Literature DB >> 15197583

Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target.

Su-Hyeong Kim1, Sang-Hyun Song, Sang-Gyun Kim, Kyung-Soo Chun, So-Young Lim, Hye-Kyung Na, Jae Weon Kim, Young-Joon Surh, Yung-Jue Bang, Yong-Sang Song.   

Abstract

PURPOSE: Recently, many studies have shown that celecoxib induces apoptosis in various cancer cells by different mechanisms depending on the cell type. This study examined the apoptotic effect of celecoxib in cervical cancer cells and its mechanism.
METHODS: Cell viability was measured by MTT assay and apoptosis was examined by DNA fragmentation and flow cytometry. Western blotting and immunoprecipitation were used to explore various mechanisms of celecoxib-induced apoptosis. The activation of NF-kappaB was confirmed by EMSA.
RESULTS: Celecoxib induced apoptosis independent of COX-2 activity. This event accompanied the activation of caspase-8 and -9 with Bid cleavage and the loss of mitochondrial membrane potential. The protective effect of caspase-8 and -9 inhibitors on celecoxib-induced apoptosis suggests the importance of caspase-8 and -9 activation in this apoptotic pathway. Fas/FADD-mediated apoptotic pathway was detected only in C33A cells, demonstrated by the immunoprecipitation of Fas-FADD in celecoxib-treated cells and the protective effect of FADD dominant negative mutant. Finally, NF-kappaB appeared to be involved in celecoxib-induced apoptosis, as revealed by increased NF-kB DNA binding activity in a time-dependent manner and attenuation of its proapoptotic effect by N-tosyl-L-phenylalanyl-chloromethyl ketone, an NF-kB blocker.
CONCLUSIONS: These data show that caspase-8 and -9 are involved in the apoptotic effect of celecoxib in cervical cancer cells. This requires the FADD-dependent pathway in a cell type-specific manner. In addition, NF-kappaB may play a key role in celecoxib-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197583     DOI: 10.1007/s00432-004-0567-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  58 in total

1.  Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB.

Authors:  E Niederberger; I Tegeder; G Vetter; A Schmidtko; H Schmidt; C Euchenhofer; L Bräutigam; S Grösch; G Geisslinger
Journal:  FASEB J       Date:  2001-07       Impact factor: 5.191

Review 2.  Cyclooxygenases 1 and 2.

Authors:  J R Vane; Y S Bakhle; R M Botting
Journal:  Annu Rev Pharmacol Toxicol       Date:  1998       Impact factor: 13.820

3.  Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac.

Authors:  B Agarwal; C V Rao; S Bhendwal; W R Ramey; H Shirin; B S Reddy; P R Holt
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

4.  Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression.

Authors:  Y Higashi; T Kanekura; T Kanzaki
Journal:  Int J Cancer       Date:  2000-06-01       Impact factor: 7.396

5.  Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.

Authors:  Xueqin Song; Ho-Pi Lin; Amy J Johnson; Ping-Hui Tseng; Ya-Ting Yang; Samuel K Kulp; Ching-Shih Chen
Journal:  J Natl Cancer Inst       Date:  2002-04-17       Impact factor: 13.506

6.  Transcriptional silencing of Cyclooxygenase-2 by hyper-methylation of the 5' CpG island in human gastric carcinoma cells.

Authors:  S H Song; H S Jong; H H Choi; H Inoue; T Tanabe; N K Kim; Y J Bang
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

7.  Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.

Authors:  Carsten Denkert; Martin Köbel; Sören Pest; Ines Koch; Stefan Berger; Michael Schwabe; Antje Siegert; Angela Reles; Bernd Klosterhalfen; Steffen Hauptmann
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

8.  Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.

Authors:  Gudrun Totzke; Klaus Schulze-Osthoff; Reiner U Jänicke
Journal:  Oncogene       Date:  2003-09-11       Impact factor: 9.867

9.  Celecoxib activates a novel mitochondrial apoptosis signaling pathway.

Authors:  Verena Jendrossek; René Handrick; Claus Belka
Journal:  FASEB J       Date:  2003-06-17       Impact factor: 5.191

10.  Aspirin induces cell death and caspase-dependent phosphatidylserine externalization in HT-29 human colon adenocarcinoma cells.

Authors:  E Castaño; M Dalmau; M Barragán; G Pueyo; R Bartrons; J Gil
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more
  20 in total

Review 1.  Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.

Authors:  Leyte L Winfield; Florastina Payton-Stewart
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

2.  Phase 0 of the Xenobiotic Response: Nuclear Receptors and Other Transcription Factors as a First Step in Protection from Xenobiotics.

Authors:  William S Baldwin
Journal:  Nucl Receptor Res       Date:  2019-11-20

3.  Anti-inflammatory drugs and uterine cervical cancer cells: Antineoplastic effect of meclofenamic acid.

Authors:  Alejandro D Soriano-Hernandez; Daniela Madrigal-Pérez; Hector R Galvan-Salazar; Margarita L Martinez-Fierro; Laura L Valdez-Velazquez; Francisco Espinoza-Gómez; Oscar F Vazquez-Vuelvas; Bertha A Olmedo-Buenrostro; Jose Guzman-Esquivel; Iram P Rodriguez-Sanchez; Agustin Lara-Esqueda; Daniel A Montes-Galindo; Ivan Delgado-Enciso
Journal:  Oncol Lett       Date:  2015-08-07       Impact factor: 2.967

4.  The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway.

Authors:  Gangadhara Reddy Sareddy; Khamushavalli Geeviman; Chinta Ramulu; Phanithi Prakash Babu
Journal:  J Neurooncol       Date:  2011-08-17       Impact factor: 4.130

5.  Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells.

Authors:  Zhihong Yang; Hang Xiao; Huanyu Jin; Phillip T Koo; Dorothea J Tsang; Chung S Yang
Journal:  Int J Cancer       Date:  2010-02-15       Impact factor: 7.396

6.  Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest.

Authors:  Ji Yeon Baek; Wonhee Hur; Jin Sang Wang; Si Hyun Bae; Seung Kew Yoon
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

Review 7.  Gene discovery in cervical cancer : towards diagnostic and therapeutic biomarkers.

Authors:  Cara M Martin; Louise Kehoe; Cathy O Spillane; John J O'Leary
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

8.  Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation.

Authors:  James Todd Auman; Robert Church; Soo-Youn Lee; Mark A Watson; James W Fleshman; Howard L Mcleod
Journal:  Eur J Cancer       Date:  2008-07-22       Impact factor: 9.162

9.  Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.

Authors:  John Hayslip; Uzair Chaudhary; Mark Green; Mario Meyer; Steven Dunder; Carol Sherman; Shanta Salzer; Andrew Kraft; Alberto J Montero
Journal:  BMC Cancer       Date:  2007-12-03       Impact factor: 4.430

10.  COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro.

Authors:  Huan-Ching Chuang; Adel Kardosh; Kevin J Gaffney; Nicos A Petasis; Axel H Schönthal
Journal:  Mol Cancer       Date:  2008-05-16       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.